CP
BNTX icon

Castleview Partners’s BioNTech BNTX Stock Holding History

Castleview Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$161K Buy
+719
New +$136K 0.07% 236

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Castleview Partners's BNTX Position: Q2 2021 in Review

Castleview Partners opened a new position in BioNTech (BNTX) in Q2 2021: 719 shares worth $161K. The stake represents 0.07% of the portfolio and ranks #236 among its holdings.

284 funds tracked by Wall St. Rank hold BNTX as of Q2 2021.

  • Castleview Partners held 719 shares of BioNTech worth $161K as of Q2 2021.
  • BioNTech was a new Castleview Partners position in Q2 2021.
  • BioNTech made up 0.07% of Castleview Partners's portfolio in Q2 2021, its #236 holding.
  • 284 funds tracked by Wall St. Rank held BioNTech as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.